Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -55,020 | -39,231 | -19,294 | -63,308 | -45,968 |
| Depreciation Amortization | -3,849 | -2,277 | -1,013 | -990 | -215 |
| Other Working Capital | 2,715 | 3,115 | -553 | 1,992 | 2,055 |
| Other Operating Activity | 10,392 | 7,165 | 3,436 | 10,989 | 7,902 |
| Operating Cash Flow | $-45,762 | $-31,228 | $-17,424 | $-51,317 | $-36,226 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 47,210 | 31,891 | 19,820 | -220,108 | -219,340 |
| PPE Investments | -229 | -176 | -87 | -879 | -591 |
| Investing Cash Flow | $46,981 | $31,715 | $19,733 | $-220,987 | $-219,931 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 223 | 210 | N/A | 662 | 532 |
| Other Financing Activity | 0 | 0 | 0 | -427 | -427 |
| Financing Cash Flow | $223 | $210 | $N/A | $235 | $105 |
| Beginning Cash Position | 26,500 | 26,500 | 26,500 | 298,569 | 298,569 |
| End Cash Position | 27,942 | 27,197 | 28,809 | 26,500 | 42,517 |
| Net Cash Flow | $1,442 | $697 | $2,309 | $-272,069 | $-256,052 |
| Free Cash Flow | |||||
| Operating Cash Flow | -45,762 | -31,228 | -17,424 | -51,317 | -36,226 |
| Capital Expenditure | -229 | -176 | -87 | -918 | -630 |
| Free Cash Flow | -45,991 | -31,404 | -17,511 | -52,235 | -36,856 |